A new collaboration aimed at accelerating the discovery of novel targets in neurodegenerative diseases utilizing our proprietary screening platform and GHI's extensive biobank resources.
CAMBRIDGE, Mass. — Nexalife Pharmaceuticals and the Global Health Institute (GHI) today announced a multi-year strategic research collaboration. This partnership brings together Nexalife's cutting-edge drug discovery engine with GHI's world-class biological databanks to identify and validate new therapeutic targets for Alzheimer's and Parkinson's disease.
Under the terms of the agreement, Nexalife will have exclusive rights to develop and commercialize any compounds resulting from this collaboration. This alliance underscores our commitment to open innovation and leveraging external expertise to tackle the most challenging medical problems.